Preparation method of high-quality erythromycin lactobionate
Through pretreatment of erythromycin and lactoic acid and vehicle crystallization, the problems of poor clarity and long dissolution time of erythromycin lactonic acid products were solved, and high-quality erythromycin lactonic acid was prepared, suitable for injections, with Good clarity and stability.
Patent Information
- Application Number
- CN202411173827.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-26
- Publication Date
- 2024-12-03
AI Technical Summary
The erythromycin lactonic acid products prepared by the prior art have poor clarity, high impurity content, and long dissolution time, which affects the quality properties of the injection.
After pretreatment of erythromycin and lactoic acid, a clear erythromycin lactonic acid solution was formed by decolorization and adsorption and heating treatment of activated carbon, and the product was quickly precipitated by the solvent crystallization method to improve the dissolution speed and clarity.
The prepared erythromycin lactonic acid product has good clarity, fast dissolution speed, low impurity content, and is suitable for injections and has improved stability.
Smart Images

Figure CN119060111A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of drug preparation, and in particular to a method for preparing high-quality erythromycin lactobionate. Background Art
[0002] Erythromycin is an alkaline antibiotic produced by Streptomyces and belongs to the macrolide class. Erythromycin is an antibacterial agent, but it also has a bactericidal effect on highly sensitive bacteria at high concentrations. Its mechanism of action is that it can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor position ("P" position), blocking the transfer RNA (tRNA) from binding to the "P" position, and also blocking the displacement of the polypeptide chain from the acceptor position ("A" position) to the "P" position, inhibiting bacterial protein synthesis, thereby exerting an antibacterial effect. It has strong antibacterial activity against Gram-positive bacteria and is used to treat many bacterial infections.
[0003] Lactobionic acid is an organic compound, a type of fruit acid, which is an acid generated by replacing the terminal hydroxyl group on lactose with a carboxyl group. The structure of lactobionic acid contains eight groups of hydroxyl and water groups, which can combine with water molecules. The chemical formula of lactobionic acid is C 12 H 22 O 12 , it is a colorless crystalline or powdered solid, soluble in water and alcohol solvents. Lactobionic acid has a variety of applications in the pharmaceutical field, mainly including enhancing the solubility and stability of drugs, improving oral absorption of drugs, etc.
[0004] Since erythromycin has poor water solubility, if it is to be prepared into an injection, it must be made into a pharmaceutical salt to increase its solubility in water. Erythromycin is an alkaline substance that can form salts with lactobionic acid. The introduction of lactobionic acid can increase the solubility of erythromycin in water, making it easier for the human body to absorb and utilize, which helps to improve the bioavailability and efficacy of the drug; erythromycin may decompose or degrade under some conditions, resulting in drug failure. The combination of lactobionic acid can improve the stability of erythromycin and extend the shelf life of the drug.
[0005] Erythromycin lactobionate is a macrolide antibiotic that has been used clinically. It has significant antibacterial effects on Gram-positive bacteria such as Staphylococcus aureus, hemolytic Streptococcus, Pneumococcus, and Corynebacterium diphtheriae. It also has antibacterial effects on some Gram-negative bacteria such as Neisseria meningitidis, Bordetella pertussis, and Bordetella influenzae.
[0006] Erythromycin lactobionate is a crystalline solid, usually a colorless or slightly yellow crystalline powder, which is soluble in water or ethanol, slightly soluble in acetone, insoluble in ether, and has good stability under acidic conditions. Erythromycin lactobionate often appears in the form of tablets, capsules or injections in the pharmaceutical field. Since erythromycin lactobionate is water-soluble, it can be administered intravenously. When oral administration is difficult or in an emergency, erythromycin lactobionate for injection can be administered by intravenous drip.
[0007] US Patent No. 2761859A discloses a method for preparing a water-soluble salt of erythromycin. First, an acetone solution of erythromycin and an aqueous solution of lactobionic acid are mixed and reacted to form a salt, and then concentrated to obtain an oily substance. Subsequently, the oily substance is dissolved in water and freeze-dried to obtain erythromycin lactobionic acid.
[0008] Chinese patent CN101624412A discloses macrolide derivatives and their preparation and use, wherein the method comprises the following steps: adding an organic acid or inorganic acid solution in a molar ratio into a reaction vessel containing erythromycin and water, stirring, controlling the temperature between -10°C and 30°C, reacting for 0.5h to 24h, and after the reaction is completed, decolorizing with activated carbon or filtering with an ultrafiltration membrane, freezing to -70°C to -30°C, and vacuum drying to obtain a hydrate of an organic acid salt or an inorganic acid salt of erythromycin.
[0009] Chinese patents CN104341474A and CN104819622A disclose a method for preparing an aqueous solution of erythromycin lactobionate and a method for freeze drying. Sodium lactobionate is exchanged and separated by a cation exchange resin column to prepare an aqueous solution of lactobionate, which is slowly dripped into a suspension of erythromycin in water to generate a salt-forming reaction, and then the erythromycin lactobionate aqueous solution is obtained by constant volume and decarbonization; the freeze drying process adopts a heating method of first fast and then slow to prepare the erythromycin lactobionate product.
[0010] However, the products prepared by the above patents and prior art have the problems of poor clarity, high impurity content in related substance detection, long dissolution time, etc., and these quality attributes have a great impact on erythromycin lactobionate in the form of injection. In order to solve the problems of poor clarity, high impurity content in related substance detection, and long dissolution time in the products prepared by the prior art, the present invention provides a preparation method of erythromycin lactobionate. Summary of the invention
[0011] In view of the above problems, the present invention provides a method for preparing high-quality erythromycin lactobionate. In the method, erythromycin and lactobionic acid are pretreated before the reaction. The obtained erythromycin lactobionate has fast dissolution speed, good clarity, good product stability and low content of related substance impurities.
[0012] To achieve the above purpose, the technical solution adopted by the present invention is as follows:
[0013] The present invention provides a method for preparing high-quality erythromycin lactobionate, comprising the following steps:
[0014] S1. Mix erythromycin with a solvent, heat until dissolved, decolorize and adsorb on activated carbon to obtain an erythromycin solution;
[0015] S2. Lactobionic acid and water are mixed, heated until dissolved, and decolorized and adsorbed on activated carbon to obtain a lactobionic acid aqueous solution;
[0016] S3. The lactobionic acid aqueous solution obtained in S2 is mixed with the erythromycin solution obtained in S1, and reacted to obtain a lactobionic acid erythromycin solution;
[0017] S4. The erythromycin lactobionate solution obtained in S3 is crystallized through a solvent to obtain erythromycin lactobionate.
[0018] Preferably, the solvent described in S1 is selected from at least one of methanol, ethanol, acetone and isopropanol; further preferably, the solvent described in S1 is selected from at least one of methanol, ethanol and acetone.
[0019] Preferably, the heating temperature in S1 is 25°C-55°C; further preferably, the heating temperature in S1 is 30°C-50°C.
[0020] Preferably, the temperature of the decolorization adsorption in S1 is 25°C-55°C, and the time is 0.2h-1.2h; further preferably, the temperature of the decolorization adsorption in S1 is 30°C-50°C, and the time is 0.5h-1h.
[0021] Preferably, the molar concentration of the erythromycin solution described in S1 is 0.35 mol / L-0.75 mol / L; further preferably, the molar concentration of the erythromycin solution described in S1 is 0.4 mol / L-0.7 mol / L.
[0022] Preferably, the heating temperature in S2 is 40°C-55°C; further preferably, the heating temperature in S2 is 40°C-50°C.
[0023] Preferably, the temperature of the decolorization adsorption in S2 is 40°C-55°C, and the time is 0.2h-1.2h; further preferably, the temperature of the decolorization adsorption in S2 is 40°C-50°C, and the time is 0.5h-1h.
[0024] Preferably, the molar concentration of the lactobionic acid aqueous solution described in S2 is 1.1 mol / L-1.5 mol / L; further preferably, the molar concentration of the lactobionic acid aqueous solution described in S2 is 1.2 mol / L-1.4 mol / L.
[0025] Preferably, the molar ratio of the lactobionic acid aqueous solution in S3 to the erythromycin and lactobionic acid in the erythromycin solution is 0.9-1.1:1; further preferably, the molar ratio of the lactobionic acid aqueous solution in S3 to the erythromycin and lactobionic acid in the erythromycin solution is 0.95-1.05:1.
[0026] Preferably, the reaction temperature of S3 is 30°C-55°C, and the reaction time is 0.5h-6.5h; further preferably, the reaction temperature of S3 is 30°C-50°C, and the reaction time is 0.5h-6h.
[0027] Preferably, the specific operation of the solvent crystallization in S4 is: adding the erythromycin lactobionate solution obtained in S3 to a poor solvent for erythromycin lactobionate, filtering, eluting and drying the product after it precipitates, to obtain erythromycin lactobionate.
[0028] Preferably, the poor solvent is selected from at least one of acetone, acetonitrile, ethyl acetate, methyl tert-butyl ether and tetrahydrofuran; further preferably, the poor solvent is selected from at least one of acetone and acetonitrile; more preferably, the poor solvent is acetone or acetonitrile.
[0029] Preferably, the poor solvent is precooled at a temperature of -45°C to -5°C; more preferably, the poor solvent is precooled at a temperature of -40°C to -10°C.
[0030] Preferably, the volume ratio of the poor solvent to the solvent described in S1 is 1:1.8-4.2; further preferably, the volume ratio of the poor solvent to the solvent described in S1 is 1:2-4.
[0031] Compared with the prior art, the present invention has the following beneficial effects:
[0032] 1. The present invention pre-treats the erythromycin solution, heats it to a clear solution, decolorizes it with activated carbon, and then filters it, thereby removing impurities in the solution and obtaining a clearer solution, thereby improving the problem of low clarity of erythromycin lactobionate prepared by the prior art.
[0033] 2. The present invention heats the lactobionic acid aqueous solution to 40°C-50°C for pretreatment, so that the acid lactobionic acid in the lactobionic acid aqueous solution increases and the ester lactobionic acid decreases, which is conducive to the reaction of salt formation and avoids the generation of other impurities.
[0034] 3. The problem of low clarity of erythromycin lactobionic acid prepared by the prior art is solved by pretreating the erythromycin solution and the lactobionic acid solution. The clarity of the obtained product is less than that of 0.5 turbidity liquid.
[0035] 4. In order to solve the problem of slow dissolution rate of erythromycin lactobionate, the present invention selects a solvent crystallization method, and reversely adds the erythromycin lactobionate solution into a pre-cooled poor solvent to quickly precipitate the obtained product, which has a faster dissolution rate compared with the freeze-dried preparation product.
[0036] The product prepared by the method provided by the invention has fast dissolution speed, good clarity, good stability and low content of related substances, and is suitable for erythromycin lactobionate injection. BRIEF DESCRIPTION OF THE DRAWINGS
[0037] Figure 1 The XRD spectrum of the erythromycin lactobionate sample obtained in Example 1;
[0038] Figure 2 This is the XRD spectrum of commercially available freeze-dried samples;
[0039] Figure 3 This is a microscope picture of the erythromycin lactobionate sample obtained in Example 1;
[0040] Figure 4 This is a microscope picture of a commercially available freeze-dried sample;
[0041] Figure 5 This is the TG detection graph of the erythromycin lactobionate sample obtained in Example 1;
[0042] Figure 6 This is the HPLC detection spectrum of the product in Example 3. DETAILED DESCRIPTION
[0043] In order to make the technical means, creative features, purpose and effect of the present invention easy to understand, the present invention is further explained below in conjunction with specific embodiments, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without making creative work all belong to the protection scope of the present invention. It is worth noting that the raw materials used in the present invention are all common commercial products, and their sources are not specifically limited. The technology and scientific terms used in the embodiments have the meanings commonly understood by those of ordinary skill in the art to which the present invention belongs.
[0044] Example 1
[0045] S1. Add 20.00 g (27.3 mmol) of erythromycin to 40 mL of ethanol, heat at 30°C until dissolved, add 0.40 g of activated carbon, stir and decolorize for 0.5 h, and filter to obtain erythromycin solution.
[0046] S2. Mix 9.78 g (27.3 mmol) of lactobionic acid and 20 mL of water, heat at 40°C until dissolved, add 0.40 g of activated carbon after dissolving, stir and decolorize for 0.5 h, and filter to obtain a lactobionic acid aqueous solution.
[0047] S3. Add the lactobionic acid aqueous solution obtained in S2 into the erythromycin solution obtained in S1, stir and control the temperature at 30°C for 0.5h to obtain a clear erythromycin lactobionic acid solution.
[0048] S4. Acetone was precooled to -10°C, and the clear solution of erythromycin lactobionate obtained in S3 was added to 160 mL of precooled acetone. The system temperature was controlled at -20°C to -10°C. The product precipitated quickly, was filtered and rinsed with acetone, and dried at 50°C to 60°C to obtain 27.62 g of a white powdery solid with a yield of 92.7%.
[0049] HPLC revealed that the retention time of the main peak of the sample was consistent with that of the main peak of the erythromycin reference substance, total impurities were 1.52%, other impurities were 0.07%, the content of erythromycin lactobionate was 98.6%, and the water content was 3.54%.
[0050] Example 2
[0051] S1. Add 20.00 g (27.3 mmol) of erythromycin to 60 mL of acetone, heat at 50°C until dissolved, add 0.40 g of activated carbon, stir and decolorize for 1.0 h, and filter to obtain erythromycin solution.
[0052] S2. Mix 10.21 g (28.5 mmol) of lactobionic acid and 20 mL of water, heat to 50°C until dissolved, add 0.40 g of activated carbon after dissolution, stir and decolorize for 1.0 h, and filter to obtain a lactobionic acid aqueous solution.
[0053] S3. Add the lactobionic acid aqueous solution obtained in S2 into the erythromycin solution obtained in S1, stir and control the temperature at 50°C for 4 hours to obtain a clear lactobionic acid erythromycin solution.
[0054] S4. Acetone was precooled to -20°C, and the clear solution of erythromycin lactobionate obtained in S3 was added into 120 mL of precooled acetonitrile. The system temperature was controlled at -30°C to -20°C. The product precipitated quickly, and after filtration, it was rinsed with acetonitrile and dried at 50°C to 60°C to obtain 26.92 g of a white powdery solid with a yield of 90.4%.
[0055] HPLC revealed that the retention time of the main peak of the sample was consistent with that of the main peak of the erythromycin reference substance, total impurities were 2.19%, other impurities were 0.18%, the content of erythromycin lactobionate was 99.3%, and the water content was 3.05%.
[0056] Example 3
[0057] S1. Add 40.00 g (54.5 mmol) of erythromycin to 80 mL of methanol, heat at 35°C until dissolved, add 0.80 g of activated carbon after dissolution, stir to decolorize and adsorb for 0.5 h, and then filter to obtain erythromycin solution.
[0058] S2. Mix 18.60 g (51.9 mmol) of lactobionic acid and 44 mL of water, heat at 45°C until dissolved, add 0.80 g of activated carbon after dissolution, stir and decolorize for 1.0 h, and filter to obtain a lactobionic acid aqueous solution.
[0059] S3. Add the lactobionic acid aqueous solution obtained in S2 into the erythromycin solution obtained in S1, stir and control the temperature at 40°C for 6 hours to obtain a clear lactobionic acid erythromycin solution.
[0060] S4. Acetone was precooled to -40°C, and the clear solution of erythromycin lactobionate obtained in S3 was added to 320 mL of precooled acetone. The system temperature was controlled at -40°C to -30°C, and the product precipitated quickly. After filtration, the product was rinsed with acetone and dried at 50°C to 60°C to obtain 55.72 g of a white powdery solid with a yield of 93.6%.
[0061] HPLC revealed that the retention time of the main peak of the sample was consistent with that of the main peak of the erythromycin reference substance, total impurities were 1.52%, other impurities were 0.07%, the content of erythromycin lactobionate was 98.9%, and the water content was 2.56%.
[0062] Comparative Example 1
[0063] S1. Add 20.00 g (27.3 mmol) of erythromycin to 40 mL of ethanol, decolorize with activated carbon, adsorb, and filter, and heat at 30°C until dissolved to obtain an erythromycin solution;
[0064] S2. 9.78 g (27.3 mmol) of lactobionic acid was mixed with 20 mL of water, stirred at 15 ° C to dissolve, decolorized with activated carbon, and then filtered to obtain an aqueous solution of lactobionic acid;
[0065] S3. The lactobionic acid aqueous solution obtained in S2 was added to the erythromycin solution obtained in S1, and the mixture was stirred and reacted at 30°C for 0.5h to obtain a clear lactobionic acid erythromycin solution;
[0066] S4. Acetone was precooled to -10°C, and the clear solution of erythromycin lactobionate obtained in S3 was added to 160 mL of precooled acetone. The system temperature was controlled at -20°C to -10°C. The product precipitated quickly, and after filtration, it was rinsed with acetone and dried at 50°C to 60°C to obtain 26.55 g of a white powdery solid with a yield of 89.2%.
[0067] HPLC revealed that the retention time of the main peak of the sample was consistent with that of the main peak of the erythromycin reference substance, total impurities were 1.86%, other impurities were 0.04%, the content of erythromycin lactobionate was 99.8%, and the water content was 2.89%.
[0068] Comparative Example 2
[0069] Compared with Example 1, the only difference is that S1 and S2 are not adsorbed by activated carbon.
[0070] Specifically:
[0071] S1. Add 20.00 g (27.3 mmol) of erythromycin to 40 mL of ethanol and heat at 30°C until dissolved to obtain erythromycin solution.
[0072] S2. Mix 9.78 g (27.3 mmol) of lactobionic acid and 20 mL of water, and heat at 40°C until dissolved to obtain a lactobionic acid aqueous solution.
[0073] S3. Add the lactobionic acid aqueous solution obtained in S2 into the erythromycin solution obtained in S1, stir and control the temperature at 30°C for 0.5h to obtain a clear erythromycin lactobionic acid solution.
[0074] S4. Acetone was precooled to -10°C, and the clear solution of erythromycin lactobionate obtained in S3 was added to 160 mL of precooled acetone. The system temperature was controlled at -20°C to -10°C. The product precipitated quickly, was filtered and rinsed with acetone, and dried at 50°C to 60°C to obtain 26.98 g of a white powdery solid with a yield of 90.6%.
[0075] HPLC showed that the retention time of the main peak of the sample was consistent with that of the main peak of the erythromycin reference substance, total impurities were 1.82%, other impurities were 0.11%, the content of erythromycin lactobionate was 97.6%, and the water content was 4.15%.
[0076] Comparative Example 3
[0077] Compared with Example 1, the only difference is that S2 "heating at 40°C until dissolved" is changed to "heating at 30°C until dissolved".
[0078] 27.7 g of white powdery solid was obtained, with a yield of 93.1%.
[0079] HPLC revealed that the retention time of the main peak of the sample was consistent with that of the main peak of the erythromycin reference substance, total impurities were 2.47%, other impurities were 0.22%, the content of erythromycin lactobionate was 98.1%, and the water content was 3.12%.
[0080] The properties of Examples 1-3 and Comparative Examples 1-3 and a commercially available lyophilized preparation were compared and tested, and the commercially available lyophilized preparation was Hospira, 38555CA.
[0081] Test Example 1: Take 0.85g of the sample to be tested, add 10mL of water to dissolve it, and compare it with No. 0.5 and No. 1 turbidity standard solutions to detect the pH of the solution;
[0082] Test Example 2: Take 0.75 g of the sample to be tested containing erythromycin lactobionate, add it into a 15 mL vial, seal it with a press cap, add 10 mL of water to the syringe and shake to dissolve, and record the dissolution time.
[0083] The re-dissolution time detection data is shown in Table 1 below:
[0084] Table 1.
[0085] Clarity pH Reconstitution time Example 1 ≤0.5 turbidity liquid 7.22 30s Example 2 ≤0.5 turbidity liquid 6.89 45s Example 3 ≤0.5 turbidity liquid 7.01 40s Comparative Example 1 >No.1 turbidity liquid 7.13 55s Comparative Example 2 >No. 2 turbidity solution 7.09 47s Comparative Example 3 >No.1 turbidity liquid 7.81 63s Original freeze-dried preparation ≤ No.1 turbidity liquid 7.19 80s
[0086] Through the clarity test, it was found that the clarity of the products obtained in Examples 1-3 was ≤0.5 turbidity liquid, and the clarity of the products obtained in Comparative Examples 1-3 was >1 turbidity liquid or even higher; the pH of the products obtained in Examples 1-3 was between 6.5-7.5, and the reconstitution time was ≤45s, and the reconstitution time of the products obtained in Comparative Examples 1-3 was >45s; the commercially available freeze-dried preparations had a clarity of ≤1 turbidity liquid, a pH of 7.19, and a reconstitution time of 80s. It can be seen that the reconstitution time of the products obtained in the comparative examples and the commercially available freeze-dried preparations is longer than that of the products obtained in the examples.
[0087] By comparing Example 1 with Comparative Examples 1-3, it is found that the clarity of the product obtained by pre-treating the lactobionic acid aqueous solution and erythromycin solution with activated carbon for decolorization and adsorption before salt formation is significantly lower than that of the No. 1 turbidity solution, and the clarity is significantly improved compared with the salt-forming products of the lactobionic acid aqueous solution and erythromycin solution without pretreatment. The reasons are mainly attributed to two points. First, the decolorization and adsorption of activated carbon can remove trace impurities that affect the clarity of the product; second, the study found that after the lactobionic acid aqueous solution was pre-treated by heating at 40°C-50°C, the acid lactobionic acid in the lactobionic acid aqueous solution increased and the ester lactobionic acid decreased, which is more conducive to the reaction of salt formation.
[0088]
[0089] Test Example 3: The relevant substances were detected according to the EP Pharmacopoeia method. The products obtained in Examples 1-3 and Comparative Examples 1-3 and commercially available freeze-dried preparations were tested by HPLC. The comparison of the relevant substance detection data is shown in Table 2 below.
[0090] Table 2.
[0091]
[0092] The detection spectrum of the relevant substances and the calculation method of the impurity content are taken as an example of the sample in Example 3. The detection spectrum is shown in Figure 6 , the impurity content is calculated as shown in Table 3 below.
[0093] Table 3.
[0094]
[0095] Comparing the detection data of related substances, the total impurities of the product obtained in the embodiment are significantly lower than those of commercially available freeze-dried preparations, and the related substances are significantly superior to those of commercially available freeze-dried preparations.
[0096] Test 4: Under accelerated conditions of temperature 40°C and humidity 75%, the stability of related substances of Example 1, Example 2 samples, Comparative Examples 1-3 and commercially available freeze-dried preparation samples were compared and tracked. Specific comparative tracking test data are shown in Table 4 below.
[0097]
[0098] According to the stability data of the product obtained in Example 2 and the commercially available lyophilized preparation under accelerated conditions in the above table, both the product obtained in Example 2 and the original lyophilized preparation showed good stability, and no significant increase in impurities was observed under accelerated conditions for 3 months.
[0099] The product obtained by reversely adding the erythromycin lactobionate solution into a pre-cooled poor solvent for rapid precipitation has a faster dissolution rate compared with a freeze-dried preparation product and a low content of related substance impurities. The present invention uses a low-temperature rapid crystallization method to obtain erythromycin lactobionate with a pH of 6.5-7.5, a product clarity that is significantly lower than that of No. 1 turbidity solution, and good product stability.
[0100] Figure 1 , Figure 2 They are respectively the XRD spectra of Example 1 and the commercially available freeze-dried sample; the erythromycin lactobionate available in the market and reported in patents is mainly a freeze-dried product and a hydrate product. Figure 1 , Figure 2 As shown, by X-ray powder diffraction (XRD) detection, it was found that the main characteristic peaks of erythromycin lactobionate in Example 1 were 4.225°, 6.545°, 6.987°, 8.320°, 8.738°, 10.426°, and 17.596°, while the main characteristic peaks of the commercially available freeze-dried sample were 4.334°, 6.353°, 9.216°, 15.401°, and 18.651°. The commercially available freeze-dried preparation is Hospira, 38555CA. There are obvious differences between the two, indicating that the product prepared by this method and the freeze-dried process product are different crystal forms; Figure 3 , Figure 4 As shown in the microscope photos of the erythromycin lactobionate sample and the lyophilized sample obtained in Example 1, the erythromycin lactobionate sample obtained in the present invention is a uniform rod-shaped or needle-shaped solid, and the lyophilized sample is an irregular agglomerated block solid. In summary, based on the difference in crystal form, the difference in dissolution rate between the two can be reasonably explained.
[0101] like Figure 5As shown, the moisture content of the erythromycin lactobionate sample obtained in Example 1 was 3.54%. After thermogravimetric (TG) detection, the product slowly lost weight at about 50°C. When the temperature was raised to 100°C, the weight initially tended to be stable. At this time, the weight loss was about 3.79%, which was basically equivalent to the moisture content of the product. The weight loss at this stage was the slow loss of moisture. Comprehensive analysis of the TG results shows that the water content of the sample prepared by this method is free water, not crystalline water. The preparation method of erythromycin lactobionate disclosed in Chinese patent CN101624412A prepares products of erythromycin lactobionate, including 3 hydrates, 3.5 hydrates, 5 hydrates, 6 hydrates, and 11 hydrates, while the sample prepared by this method is erythromycin lactobionate with non-crystalline water, and the two also have different crystal forms.
[0102] Finally, it should be noted that the above content is only used to illustrate the technical solution of the present invention, rather than to limit the scope of protection of the present invention. Simple modifications or equivalent substitutions of the technical solution of the present invention by ordinary technicians in this field do not deviate from the essence and scope of the technical solution of the present invention.
Claims
1. A method for preparing high-quality erythromycin lactobionate, characterized in that: The following steps are involved: S1. Mix erythromycin and solvent, heat until dissolved, decolorize and adsorb on activated carbon to obtain erythromycin solution; S2. Lactobionic acid and water are mixed, heated until dissolved, and decolorized and adsorbed on activated carbon to obtain a lactobionic acid aqueous solution; S3. The lactobionic acid aqueous solution obtained in S2 is mixed with the erythromycin solution obtained in S1, and reacted to obtain a lactobionic acid erythromycin solution; S4. The erythromycin lactobionate solution obtained in S3 is crystallized through a solvent to obtain erythromycin lactobionate.
2. The preparation method according to claim 1, characterized in that: The solvent described in S1 is selected from at least one of methanol, ethanol, acetone and isopropanol.
3. The preparation method according to claim 1, characterized in that: The heating temperature in S1 is 25°C-55°C; the decolorization adsorption temperature in S1 is 25°C-55°C, and the time is 0.2h-1.2h.
4. The preparation method according to claim 1, characterized in that: The molar concentration of the erythromycin solution described in S1 is 0.35 mol / L-0.75 mol / L.
5. The preparation method according to claim 1, characterized in that: The heating temperature in S2 is 40°C-55°C; the decolorization adsorption temperature in S2 is 40°C-55°C, and the time is 0.2h-1.2h.
6. The preparation method according to claim 1, characterized in that: The molar concentration of the lactobionic acid aqueous solution described in S2 is 1.1 mol / L-1.5 mol / L.
7. The preparation method according to claim 1, characterized in that: The molar ratio of the lactobionic acid aqueous solution in S3 to the erythromycin and lactobionic acid in the erythromycin solution is 0.9-1.1:1; the reaction temperature in S3 is 30°C-55°C, and the reaction time is 0.5h-6.5h.
8. The preparation method according to claim 1, characterized in that: The specific operation of the solvent crystallization described in S4 is: adding the erythromycin lactobionate solution prepared in S3 to a poor solvent for erythromycin lactobionate, filtering, eluting and drying the product after it precipitates, and obtaining erythromycin lactobionate.
9. The preparation method according to claim 1, characterized in that: The poor solvent is selected from at least one of acetone, acetonitrile, ethyl acetate, methyl tert-butyl ether and tetrahydrofuran.
10. The preparation method according to claim 1, characterized in that: The poor solvent is precooled at a temperature of -45°C to -5°C.
Citation Information
Patent Citations
Derivative of macrolides, method for preparing same and application thereof
CN101624412A
Method for extracting crystallized erythromycin thiocyanate from fermentation liquid
CN103044508A
Composite solvent for extractive crystallization of erythromycin thiocyanate and extractive crystallization method
CN103483407A
Preparation method and salification reactor of erythromycin lactobionate solution
CN104341474A
Roxithromycin crystal-form compound and preparation method thereof
CN109206463A
Cited By
Method for preparing erythromycin lactobionate
CN119350403A
Freeze-drying process of erythromycin lactobionate for injection
CN119909024A
